Results 251 to 260 of about 1,468,461 (396)

PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma

Cancer Science, EarlyView.
PBK plays a crucial role in cell survival in mesothelioma and is associated with worse outcome. PBK is a promising therapeutic target that may serve as a prognostic biomarker, enabling personalized treatment of mesothelioma. ABSTRACT Mesothelioma is one of the most aggressive neoplasms worldwide that has a particularly poor prognosis.
Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Fengshi Chen‐Yoshikawa, Makoto Ishii   +12 more
wiley   +1 more source

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. [PDF]

Blood Cancer J
Golmohammadi M, Raza S, Albayyadhi M, Sholehrasa H, Khouri J, Williams L, Hansen DK, Moradi A, Xu X, Albliwi M, Ali AH, Dima D, Anwer F, Paul B, Jaberi-Douraki M.   +14 more
europepmc   +1 more source

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma [PDF]

, 2009
Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien‐Hsing Chang   +4 more
openalex   +1 more source

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt, Yohei Hashimoto, Stephanie Young, Jennifer Arnold, Justin Game, Claire Hooper, Andrew Field, Richard Barry, Daniel Barthelmes, Mark Gillies   +9 more
wiley   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Functional analysis of bispecific antibody (EpCAMxCD3)‐mediated T‐lymphocyte and cancer cell interaction by single‐cell force spectroscopy [PDF]

, 2010
Sabrina Hoffmann, Guido Wabnitz, Yvonne Samstag, Gerhard Moldenhauer, Thomas Ludwig   +4 more
openalex   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Cell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu, Chuanjiang Yang, Rui Gao, Jinzhang Zeng, Quanyi Lu, Qiang Luo, Jun Wu, Siming Chen   +18 more
wiley   +1 more source

Hematopoietic progenitor kinase-1 inhibition improves the in vitro efficacy of bispecific antibodies in CLL. [PDF]

Blood Adv
Shorer Arbel Y, Yitzhak L, Katz BZ, Herishanu Y.   +3 more
europepmc   +1 more source

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy [PDF]

, 2010
Robert M. Sharkey, Edmund A. Rossi, William J. McBride, Chien‐Hsing Chang, David M. Goldenberg   +4 more
openalex   +1 more source

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission).
Thomas Lund, Cyrus Khandanpour, Sébastien Anguille, Jens Kisro, Maria Theresa Krauth, Johan Lund, Inger Nijhof, Enrique M. Ocio, Elena Zamagni, Matthieu Javelot, Claire Albrecht, Cristina Entrala Cerezo, Aurore Perrot   +12 more
wiley   +1 more source